The Truth About Pediatric Antidepressant Use

DSpace/Manakin Repository

The Truth About Pediatric Antidepressant Use

Show simple item record

dc.contributor.advisor Peter Hutt en_US
dc.contributor.author Rostoker, Jessica
dc.date.accessioned 2012-05-19T22:50:08Z
dc.date.issued 2011
dc.identifier.citation Jessica Rostoker, The Truth About Pediatric Antidepressant Use (May 2011). en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8789619
dc.description.abstract In 2003, the FDA discovered that a number of clinical-trial adverse events from a pediatric study of the antidepressant drug Paxil involved suicidal behavior or ideation. In response, in June 2003, the FDA issued a public health advisory recommending against the use of Paxil as a pediatric antidepressant. In October of the same year, the FDA commissioned patient-level data sets from a number of antidepressant-medication manufacturers in order to have a larger set of data from which to draw conclusions about the association between pediatric use of antidepressant drugs and increased risk of suicidality. Also in October 2003, the FDA issued the first in a series of health advisories warning of an association between the use of pediatric antidepressants generally and an increase risk of suicidality. After rigorously analyzing the data from the drug-manufacturer studies, the FDA reached the conclusion that the data in aggregate indicated an increased risk of suicidality in pediatric patients. Therefore, in October 2004, the FDA announced that it would require all antidepressant medication labeling to include a black-box warning describing the increased risk of suicidality in children and adolescents. Unfortunately, by 2005, researchers documented 20-30% declines in antidepressant use by children and adolescents and a concurrent increase in the national adolescent suicide rate. Paradoxically, by attempting to protect America’s youth from an increased risk of suicide ideation and behavior, the FDA inadvertently steered vulnerable individuals away from much-needed treatment, thereby, increasing their risk of actual suicide. This paper explores the disorder of major depression, surveys the data on pediatric antidepressant use and suicidality, and evaluates the FDA’s actions in light of the unintended consequences. This paper seeks to answer the question: when faced with a medication side effect that is also a symptom of the disease, what was the FDA to do? en_US
dash.license LAA
dc.subject human drugs>>prescription drug licensure>>specific drug products en_US
dc.subject.other Food and Drug Law en_US
dc.title The Truth About Pediatric Antidepressant Use en_US
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-05-19T22:50:08Z

Files in this item

Files Size Format View
Rostoker, Jessi ... ildren and Adolescents.pdf 460.5Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters